
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a positive trajectory in its diagnostics business, as evidenced by an increase in EsoGuard tests processed, rising from 2,756 in Q2 to 2,841 in Q3, indicating a growing demand for its products. The company's valuation appears attractive, reflecting a balance between high risks and substantial upside potential, particularly as it advances its innovations in medical technology. With the ongoing commercialization of its products, expected significant growth is projected for 2025 and 2026, enhancing the overall outlook for the company's future performance.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million for the quarter, reflecting weakness in expected earnings per share compared to both internal and consensus estimates, which indicates underlying financial challenges. The company also experienced a decline in EsoGuard test volume, processing only 2,756 tests in Q2, down from previous quarters, which raises concerns about demand and operational efficiency. Additional risks include liquidity issues, the potential failure of products in clinical trials, difficulties in gaining regulatory approvals, and challenges in commercialization, all of which could impede future growth and investor confidence.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares